ArticleHealth science reports2025
Prevalence and Factors Associated With Proton Pump Inhibitors (PPIs) Use: A Cross-Sectional Study of PERSIAN Guilan Cohort Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Proton pump inhibitors (PPIs) are used extensively in the treatment of patients with upper gastrointestinal disorders. In this study, we aimed to investigate the prevalence of PPI consumption and related factors in the Prospective Epidemiological Research Studies in Iran (PERSIAN) Guilan Cohort study (PGCS) population. Methods: This was a cross-sectional study form the PGCS, and investigated 10,520 participants for PPI consumption, which were divided into two groups: users and nonusers. Demographical data, clinical characteristics, and PPI types were recorded. The data were analyzed using SPSS version 16 and GraphPad Prism version 9, and a significance level of 0.05 was considered. Results: The prevalence of PPI use in the overall participants was 4.8%, and it was higher in females compared to males (6.1% vs. 3.3%). According to the regression analysis, being in the overweight category was associated with a 26% lower likelihood of PPI use ( Conclusion: This study highlights the concerning trend of increasing PPI use and identifies low physical activity, reflux, multiple underlying diseases, and NSAID use associated with higher risk of PPI use. It emphasizes the need for caution in prescribing PPIs and raising awareness among both healthcare providers and patients about the potential risks and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.